WHO ICTRP trial
USE OF RIFAXIMIN THERAPY IN PRIMARY PREVENTION OF HEPATORENAL SYNDROME IN…
JPRN-UMIN000038487 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-UMIN000038487 |
|---|---|
| Public title | USE OF RIFAXIMIN THERAPY IN PRIMARY PREVENTION OF HEPATORENAL SYNDROME IN CIRRHOTIC PATIENTS WITH ASCITES |
| Scientific title | USE OF RIFAXIMIN THERAPY IN PRIMARY PREVENTION OF HEPATORENAL SYNDROME IN CIRRHOTIC PATIENTS WITH ASCITES - USE OF RIFAXIMIN THERAPY IN PRIMARY PREVENTION OF HEPATORENAL SYNDROME IN CIRRHOTIC PATIENTS WITH ASCITES |
| Primary sponsor | NationalAcademy of health Sciences,Bir Hospital Department Of Medicine Gastroenterology Unit |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Asia(except Japan) |
| Conditions | Liver Cirrhosis with ascites |
| Interventions | Rifaximin group ,Tab rifaximin at a dose of 550mg BD for 12 weeks and other standard treatment. Non Rifaximin group,Only standar Rx. |
| Registration date | Mar 11, 2019 |
| Target size | 94 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: